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INTRODUCTION
Acute viral hepatitis (A and E) is a predominant cause of
Fulminant Hepatic Failure (FHF) in developing countries
where viral etiology accounts for approximately 74% of
the acute FHF.1,2 It is a life-threatening and devastating
medical emergency in a previously healthy child.
Although most of the viral hepatitis is self-resolving and
causes milder disease but this could be devastating and
lethal. FHF has been classified into hyper acute, acute
and sub-acute liver failure on the basis of duration of the
disease.3 Almost all children in developing countries has
been exposed to hepatitis A by the age of 5 years.4
Children who developed FHF secondary to AVH has a
high mortality because of unavailability of specific
treatment as only supportive management is available
which is occasionally effective in such a severe and high
risk disease; whereas only a few patients recover
spontaneously.1 Orthotropic liver transplantation is the
best option in management in FHF with a good one and
5-year transplant free survival is 74% and 69%
respectively. However, unfortunately this option is either
too expensive with donor and experience limitations
leading to non-availability all around globe.5
Acetaminophen (APAP) is one of the most frequently
used analgesics, and is the most commonly used self-
poisoning substance leading to FHF in the developed
world.1,6 The most effective treatment for APAP toxicity
is N-acetylcysteine (NAC).7 NAC is a glutathione having
antioxidant properties that scavenges the free radicals
and improves hepatic blood flow via oxygen extraction
through its vasodilator property.8 Its use in non-
acetaminophen induced fulminant hepatic failure is
controversial. Some studies showed a beneficial
outcome in children who received NAC in Acute Viral
Hepatitis (AVH),9,10 while other without improvement.11,12
Recently, there is a shift of beneficial effects of NAC use
in viral etiology induced FHF.10 The two recent
randomized control trials on using NAC in non-APAP
toxicity FHF showed some marginal improvement in
outcome.12,13 Intravenous NAC versus placebo in adults
with non-APAP liver failure, NAC did not improve
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ABSTRACT
Objective: To determine the efficacy of N-acetylcysteine (NAC) in children aged > 1 month to 16 years admitted with
Fulminant Hepatic Failure (FHF) secondary to Acute Viral Hepatitis (AVH) in a tertiary care center of a developing country.
Study Design: Analytical study.
Place and Duration of Study: Department of Paediatrics, The Aga Khan University Hospital, Karachi, Pakistan, from
January 2007 to December 2011.
Methodology: Medical records of children (> 1 month - 16 years) with FHF admitted with AVH of known etiology who
received NAC were reviewed retrospectively. Liver function tests (mean ± SD) at baseline, 24 hours after NAC and before
or at the time of discharge/death were recorded and compared via using repeated measures ANOVA (r-ANOVA). Efficacy
of NAC is defined in improvement in biochemical markers, liver function test and discharge disposition (survived or died).
Mortality associated risk factors were identified by using logistic regression analysis. P-value and 95% confidence interval
were recorded.
Results: Forty children (mean age was 80 ± 40 months) with FHF secondary to AVH received NAC. Majority were males
(n=25; 63%). Vomiting (75%) and jaundice (65%) were the main presenting symptoms, one-third had hypoglycemic, while
40% had altered sensorium at the time of admission. There was significant statistical difference in liver enzymes and
prothrombin time on admission comparing at discharge in children received NAC (p < 0.001). Fifteen (38%) children died.
Severe vomiting {Odds Ratio (OR) 0.22, 95% Confidence Interval (CI) 0.05 - 0.8}, jaundice (OR 9.3, CI 1.1 - 82.6),
inotropic support (OR 20.6, CI 3.5 - 118.3) and mechanical ventilation (OR 4.3, CI 1.1 - 16.6) at the time of admission are
associated with risk factors for mortality in children with FHF secondary to AVH.
Conclusion: NAC used in children with FHF secondary to AVH is associated with markedly improved liver function tests
and recovery. FHF with complications is high risk for mortality.
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survival at 21 days. However, a sub-analysis of the
secondary outcomes revealed improved Liver Trans-
plantation (LTx)-free survival at 3 weeks for those with
grade 1 - 2 hepatic encephalopathy.13
It is difficult to draw a conclusion of NAC efficacy in
children affected by AVH in developing countries by
using these two trials because one study was on adults,
while the study on children had very few children with
AVH. Therefore, it is essential to do study in developing
country where the burden of AVH (A and E) associated
morbidity remains high,2 and liver transplantation
facilities are scarce, and available on very high cost.
The aim of this study was to assess the effectiveness in
preventing morbidity and mortality in children receiving
NAC for AVH induced FHF by measuring the change in
their laboratory and clinical parameters before, during
and after the NAC and identify the prognostic markers
for survival in children receiving NAC for AVH.
METHODOLOGY
The study was conducted at the Paediatric ICU (PICU)
of AKUH, Karachi. Medical records of patients aged one-
month to 16 years admitted in PICU with diagnosis of
FHF during 2007 - 11 were reviewed. Total 40 patients
were admitted with diagnosis of FHF secondary to
AVH and received NAC. FHF other than viral etiologies
were excluded. Data was retrieved from, (i) hospital
information system using International Classification of
Diseases (ICD-9) acute liver failure/FHF (570.0), hepatic
coma (572.2), acute hepatic necrosis (570), and (ii)
inpatient paediatric ICU registry. Use of NAC was re-
confirmed with the hospital pharmacy data base.
Paediatric acute liver failure study group (PALFSG)
definition of fulminant hepatic failure was biochemical
evidence of liver injury, no history of known chronic liver
disease, coagulopathy not corrected by vitamin K, INR
greater than 1.5 with encephalopathy or greater than 2
without encephalopathy.5,14,15 NAC was given intra-
venously as 21-hour regimen in 3 doses with cumulative
dose of 300 mg/kg over 21 hours (initial loading
dose of 150 mg/kg over one hour, followed by   50 mg/kg
for 4 hours, then continuous infusion of 100 mg/kg over
next 16 hours).16,17 Patients were observed for any sign
of anaphylaxis, hypotension and other side effects.
Demographic features, presenting complaints, con-
sciousness at the time of arrival (Glasgow Coma Scale -
GCS), laboratory and biochemical markers i.e., LFTs,
INR blood sugar levels and electrolytes, viral serology
(Hepatitis A, E,) were recorded.
Efficacy of NAC is defined in improvement in bio-
chemical markers, liver function test and discharge
disposition (survived or died).
The statistical analysis was performed by using SPSS
software package (version 20.0, SPSS). Continuous
variables (i.e., age, liver function tests, and electrolytes)
were presented in the form of mean, standard deviation
and median. Categorical variables (gender, presenting
complaints, complications and discharge disposition)
were presented in frequency and percentages.
Statistical differences in biochemical and laboratory
parameters (i.e., presenting complaints, laboratory
studies including AST, ALT, bilirubin, PT/INR and
albumin) at three point times; (i) at admission, (ii)
24 hours after NAC administration and (iii) before
discharge or death were made by repeated measures
analysis of variance (ANOVA) comparing to their
discharge disposition. Normality assumption was
checked for biochemical variables and Friedman's test
(non-parametric test for multiple comparisons for
repeated measures ANOVA) was used to compare the
variables without normal distribution. A p-value < 0.05
was considered significant. Univariate analysis was
performed, and chi-square, Odds ratio and p-value for
mortality associated risk factors in children with
AVH received NAC has been calculated. The study
was approved by the University Ethical Review Board
(2310-Ped-ERC-12).
RESULTS
Forty children with FHF secondary to AVH received NAC
(Figure 1) with mean age of 80 months (median 72
months). Majority of them were males (n=25, 63%).
Vomiting (n=30, 75%), jaundice (n=26, 65%), and fever
(n=20, 50%) were the major presenting complaints.
Eleven children presented with low GCS of 8/15 (n=11,
28%). Baseline serum LFTs at the time of admission
were ALT (mean = 2102I U/L; median = 1497 IU/L), AST
(mean = 2495 IU/L; median = 1552 IU/L), Prothrombin
time (mean = 45 seconds; median = 30 seconds), INR
(mean = 4; median = 3), total bilirubin (mean = 17 mg/dl;
median = 11 mg/dl) and albumin (mean = 2.8 gm/L;
median = 2.7 gm/L). Mean length of PICU stay was 3.4
± 2 days (median 3 days) and overall mortality rate was
375 per 1000 children developed FHF secondary to AVH
(Table I).
Table II compared the mean change in LFTs at three
time points in the children received NAC. A statistically
significant improvement in the mean laboratory
parameters has been observed in ALT, AST and PT
(p = < 0.001). Table III compared the LFTs of children
survived with those who died at three different time
points (baseline, 24-hour and before discharge or death
after NAC administration) by using r-ANOVA. There is
reversal of ALT/AST found at three time points in
children who died. There is statistically significant
differences in LFTs observed over time severely
deranged PT (p=0.01), INR (p=0.05) and a high serum
bilirubin (SBR) has been observed in children who
died (Table III). Jaundice (OR 9.3; CI = 1.1 - 82.6) at
presentation, acute kidney injury (OR 3.5; CI = 0.9 -
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14.3), need for mechanical ventilation at admission
(OR 4.3; CI = 1.1 - 16.6) and inotropic support (OR 20.6;
CI = 3.5 - 118.3) identified poor prognostic markers of
mortality at univariate analysis.
DISCUSSION
Hepatitis A is endemic in many areas of the world
including Pakistan where it has been reported to be the
main cause (10 - 50%) of FHF death.6,18-20 Although the
Hepatitis A co-infection with Hepatitis E virus has been
associated with increased mortality,21 the authors found
Hepatitis A FHF leading to mortality in more than half
(55%) of the study cohort, as observed in other studies
from the subcontinent.6,18 Medical literature about
efficacy of NAC in childhood FHF because of AVH is
very scarce and till date only two randomized clinical
trials available compared the NAC efficacy in non-APAP
FHF.12,13,22 One trial specifically in adult, with
inconclusive results,13 while one trial performed in
paediatrics,12 with limited AVH FHF pathology showed
some promising results particularly in centers without
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Figure 1: Flow diagram of study.
Table II: Comparison of changes in liver function test before and after
N-acetylcysteine in children with AVH.
Pre-NAC 24 hours Before p-value^
post-NAC discharge/death
ALT 2101 ± 1529 1019 ± 816 466 ± 495 <0.001*
AST 2500 ± 2005 528 ± 451 435 ± 431 <0.001*
PT 43.5 ± 34 31.2 ± 30 28.3 ± 33 <0.001*
INR 3.8 ± 2 3.3 ± 3 4.7 ± 9 0.51**
SBR 17.6 ± 14 17 ± 12 14.6 ± 11 0.15
Albumin 2.8 ± 0.5 2.9 ± 0.51 2.9 ± 0.5 0.16
^ Normality assumption for all above variables was checked. “Friedman's test” (Non-parametric
test for multiple comparison for repeated measures ANOVA) was used. 
*p = < 0.001, **p = 0.001 (Friedman's test).
Table III: Comparison of changes in liver function test among children
who survived compared to dead after N-acetylcysteine.
Survived Died p-value
(mean ± SD) (mean ± SD)
ALT Pre-NAC 2306 ± 1533 1734 ± 1505
24 hours post-NAC n=40* 1129 ± 855 822 ± 730 0.101
ALT before discharge 389 ± 409 603 ± 613
AST Pre-NAC 2010 ±1881 3579 ± 2027
24 hours post-NAC n=16* 482 ± 493 629 ± 367 <0.001
AST before discharge 434 ± 512 437 ± 198
PT Pre-NAC 36 ± 26 57 ± 43
24 hours post-NAC n=40* 19 ± 8 53 ± 41 0.01
AST before discharge 15 ± 4 52 ± 49
INR Pre-NAC 3.4 ± 2 4.5 ± 3
24 hours post-NAC n=40* 2.6 ± 3 4.5 ± 3 0.05
AST before discharge 1.8 ± 2 9.7 ± 15
SBR Pre-NAC 19.2 ± 17 14.8 ± 8
24 hours post-NAC n=38* 17.2 ± 13 16.8 ± 11 <0.001
AST before discharge 11.4 ± 9 20.2 ± 11
Albumin Pre-NAC 2.9 ± 0.5 2.6 ± 0.6
24 hours post-NAC n=37* 2.9 ± 0.5 2.9 ± 0.5 0.01
AST before discharge 2.8 ± 0.5 2.9 ± 0.6
* Children with all laboratories available.
Abbreviations: ALT = Alanine transaminase; AST = Aspartate transaminase; PT = Prothrombin
time; INR = International normalization ratio; SBR = Serum bilirubin.
Table I: Demographic and clinical features of study participants received
N-acetylcysteine (n=40).
Variables N (%)
Age (months) (mean ± SD) 80 ± 40
Male 25 (63)





Altered sensorium 16 (40)
Abdominal symptoms 8 (20)
Laboratories at admission
Liver function test (mean ± SD)
SGPT (ALT) (n=40) 2102 ± 1509
SGOT (AST) (n=35) 2495 ± 2786
PT (n=40) 45 ± 35
INR (n=40) 4 ± 2.3
SBR (total) (n=40) 17 ± 14
Albumin (n=37) 2.8 ± 0.5
Platelets (n=40) (mean (range) 305 ((24, 1079))
Serum sodium (n=40) (mean ± SD) 133 ± 5
Hypoglycemia* 12 (30)
Positive blood culture 9 (23)
ICU therapy
Mechanical ventilation 24 (60)
Inotropic support 19 (48)
Renal replacement therapy 5 (13)
Length of ICU stay (days) (mean ± SD) 3.4 ± 2 
Complications
AKI 12 (30)




*Hypoglycemia (random blood sugar of less than 60 mg/dl).
Abbreviations (GCS, Glasgow coma scale; ALT, alanine transaminase; AST, aspartate
transaminase; PT, Prothrombin time; INR, international normalization ratio; SBR, serum
bilirubin; AKI, acute kidney injury)
transplantation, where there is no other option for child
survival.23
Managing FHF is challenging because of its rapid
progression to coma and death. It required early
intervention and best possible supportive measures to
correct and normalize metabolic parameters to reduce
further hepatic injury.19 There was an overall steady
improvement in LFTs over time after NAC adminis-
tration. Despite the discharge disposition most of the
LFTs in this study population showed improvement after
NAC administration. However, the baseline laboratory
parameters (i.e., PT and INR) were severely deranged in
children in died group. These laboratory parameters if
severely deranged at the time of admission has a worse
prognosis.2,15,19 NAC benefits less in children with milder
hepatic encephalopathy.12 The authors observed
marked changes and gradual improvement in LFTs over
the time in children with milder hepatic encephalopathy
compared to children developed coma. Almost all
children with grade-IV hepatic encephalopathy died in
the present cohort. Encephalopathy is one the main
determinants of outcome.5 This study showed that 16
(40%) presented with altered level of consciousness
while 11 (28%) had Glasgow Coma Scale (GCS) of less
than 8; similar to previous studies and was also
associated with higher mortality.5,18,21
Most of the published medical literature proved NAC
safety in children in paracetamol induced hepatic
toxicity, and with growing literature its use in AVH
induced FHF is safe and effective.24,25 There was an
improvement in biochemical, metabolic and clinical
parameters without any adverse effect (hypotension and
anaphylaxis). The overall mortality in this study cohort
was 38%, which is much less than previously described
at other centers without liver transplant in Pakistan and
Turkey.1,18
This study showed the same bad prognostic markers as
already highlighted by many studies including
encephalopathy on presentation, raised INR and
bilirubin and a worsening trend of these parameters.1,4,22
Overall mortality due to FHF is decreasing with early
liver transplant becoming available at some centers but
it is still high (20 - 50%).1,18,22
The limitation of this study includes retrospective data;
we were not able to assess all the variables and were
limited by the completeness of documentation by the
treating physicians. It is also very difficult to ascertain the
causality and whether improvements in clinical and
laboratory parameters are due to spontaneous recovery
over time or effect of NAC in the absence of control
group. Because of the constraints of the chart review,
not all confounding variables could be dealt with, but we
performed a stringent statistical analysis i.e., repeated
measures ANOVA design and adjusted odds ratio to
reduce the impact of these variables to the lowest levels
possible. There is no comparison group. The other
possibilities for future is to either use historic control
which itself has limitations or have a prospective control
group. The authors identified certain important
prognostic risk factors for AVH mortality along with
safety and effectiveness of NAC in paediatric population
over a period of time by checking the change in hepatic
laboratory markers provides important knowledge in
AVH and NAC in developing country setting where the
hepatic transplantation facilities are essentially not
available, however, an interventional blinded design with
a comparative arm in paediatric population is important
in this field.
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Table IV: Mortality associated risk factor among children with AVH received N-acetylcysteine.
Variables Survived (n=25) Died (n=15) p-value OR (95% CI)
Male 17 (68%) 8 (53%) 0.50 0.53 (0.2 - 2.0)
Presenting complaints
Fever 14 (56%) 6 (40%) 0.51 0.52 (0.1 - 1.9)
Abdominal pain / distension 9 (36%) 4 (26%) 0.73 0.55 (0.2 - 2.6)
Vomiting 20 (80%) 7 (46%) 0.03 0.22 (0.05 - 0.8)
Jaundice 15 (60%) 14 (93%) 0.03 9.3 (1.1 - 82.6)
Altered sensorium 11 (44%) 8 (53%) 0.56 1.5 (0.4 - 5.2)
Hematemesis* 1 (04%) 2 (13%) 0.54
Complications 
Bleeding 0 3 (20%) -- --
Grade-IV coma 0 10 (66%) -- --
Acute kidney injury* 5 (20%) 7 (46%) 0.07 3.5 (0.9 - 14.3)
Hypoglycemia** 6 (24%) 6 (40%) 0.31 2.1 (0.5 - 8.4)
Electroencephalography
Diffuse delta and theta slowing 10 (40%) 6 (40%) 0.32 1.6 (0.7 - 3.8)
Mechanical ventilation* 11 (44%) 13 (87%) 0.01 4.3 (1.1 - 16.6)
Renal replacement therapy* 4 (16%) 1 (06%) 0.63 --
Inotropic therapy 6 (24%) 13 (87%) <0.001 20.6 (3.5 - 118.3)
Neuro-protective therapy 19 (76%) 12 (80%) 0.77 0.8 (0.2 - 3.8)
** Hypoglycemia (Random blood sugar <60 mg/l );   * Fischer Exact test applied
CONCLUSION
NAC use in FHF secondary to AVH is effective in
developing countries without liver transplantations
facilities. It shows improvement in LFTs and encephalo-
pathy. Further studies, including paediatric randomized
trial on FHF secondary to AVH are needed before its
routine use.
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